Biotechnology

Roivant is decanting another Vant armed with Eisai blood cancer drug, and plans to start phase 1/2 soon

Roivant Sciences has spawned another guy. The latest addition to the clan is Hemavant, a biotech company that is starting life with the former Eisai drug and plans to begin research on patients with myeladysplastic syndromes (MDS) this year.

Hemavant is developing RVT-2001, a low-molecular-weight 3B splicing subunit 3B modulator that Roivant received under license from Eisai late last year. Eisai, which works with its subsidiary H3 Biomedicine, took a candidate for oral admission into a phase 1 clinical trial in 2016, but saw no complete or partial response in the first 84 patients who participated in the study of patients with MDS and other blood cancers. .

Work with the candidate stopped after data fell in 2019, and Royvant said in January that the number of subjects treated with RVT-2001 was still “more than 80”. However, Roivant sees promising some of the data generated by Eisai, leading to asset licensing and narrowing the program’s focus.

Eisai enrolled patients with acute myeloid leukemia, chronic myelomonocytic leukemia, and low- and high-risk MDS in a phase 1 study. the future in patients at lower risk of transfusion-dependent patients with MDS.

on the topic: Roivant ditches plans to re-acquire Immunovant, investing $ 200 million

Thirty percent of the 19 lower-risk MDS patients who received RVT-2001, formerly known as H3B 8800, gained erythrocyte transfusion independence. Most patients had previously received Revlimid Bristol Myers Squibb, hypomethylating agents, or both.

Based on this signal, Hemavant is developing RVT-2001 as an oral therapy for transfusion-dependent anemia in patients at lower risk MDS. Phase 1/2 clinical trials should begin in the first half of the year.

Roivant paid Eisai $ 8 million in cash and $ 7 million in stock for global rights to the candidate. As RVT-2001 develops, Roivant will pay up to $ 65 million for development and regulatory phases on the first indication plus up to $ 18 million for additional indications. The deal also provides up to $ 295 million in commercial stages and a multi-level high single-player award.

https://www.fiercebiotech.com/biotech/roivant-decants-another-vant-armed-eisai-blood-cancer-drug-and-plans-to-start-phase-1-2 Roivant is decanting another Vant armed with Eisai blood cancer drug, and plans to start phase 1/2 soon

Back to top button